NovoCure (NVCR) Enterprise Value (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -317.84% |
| Dec 31, 2025 | 70.00% |
| Sep 30, 2025 | -126.54% |
| Jun 30, 2025 | 83.63% |
| Mar 31, 2025 | 3.20% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | -469.87% |
| Jun 30, 2024 | 80.64% |
| Mar 31, 2024 | 4.44% |
| Dec 31, 2023 | 1.15% |
| Sep 30, 2023 | -484.94% |
| Jun 30, 2023 | 15.62% |
| Mar 31, 2023 | 80.75% |
| Dec 31, 2022 | -297.25% |
| Sep 30, 2022 | 74.27% |
| Jun 30, 2022 | -394.98% |
| Mar 31, 2022 | 79.56% |
| Dec 31, 2021 | -0.42% |
| Sep 30, 2021 | -158.96% |
| Jun 30, 2021 | 58.28% |
| Mar 31, 2021 | -2.59% |
| Dec 31, 2020 | -257.96% |
| Sep 30, 2020 | 32.11% |
| Jun 30, 2020 | -89.77% |
| Mar 31, 2020 | -1.83% |
| Dec 31, 2019 | 14.63% |
| Sep 30, 2019 | 26.15% |
| Jun 30, 2019 | -10.90% |
| Mar 31, 2019 | -79.75% |
| Dec 31, 2018 | 37.31% |
| Sep 30, 2018 | -3.99% |
| Jun 30, 2018 | -92.47% |
| Mar 31, 2018 | -40.94% |
| Dec 31, 2017 | 56.73% |
| Sep 30, 2017 | -1.18% |
| Jun 30, 2017 | 2.58% |
| Mar 31, 2017 | 13.83% |
| Dec 31, 2016 | 6.76% |
| Sep 30, 2016 | -17.27% |
| Jun 30, 2016 | 14.81% |
| Mar 31, 2016 | 12.49% |
| Dec 31, 2015 | -96.20% |
| Sep 30, 2015 | -28.93% |
| Jun 30, 2015 | -43.51% |
| Mar 31, 2015 | 27.67% |
| Dec 31, 2014 | -28.30% |